Phase I Study of BI 831266 in Patients With Advanced Solid Tumours

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
The main objective of this trial is to provide safety data in terms of drug-related adverse events for the recommendation of the dose for further trials in the development of BI 831266. Secondary objectives are the collection of antitumour efficacy data and the determination of the pharmacokinetic and pharmacodynamic profile of BI 831266.
Epistemonikos ID: 1414b6bfefe82502941fcf9a6ed63ecba4f795ce
First added on: May 05, 2024